Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
71 hedge funds and large institutions have $21.3M invested in Unity Biotechnology in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 29 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 12
0.04% more ownership
Funds ownership: 2.5% → 2.53% (+0.04%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
15% less funds holding
Funds holding: 84 → 71 (-13)
19% less call options, than puts
Call options by funds: $250K | Put options by funds: $309K
41% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 29
49% less capital invested
Capital invested by funds: $42M → $21.3M (-$20.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$1.68M |
| 2 |
Renaissance Technologies
New York
|
+$955K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$807K |
| 4 |
Two Sigma Advisers
New York
|
+$803K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$609K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.63M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.03M |
| 3 |
Morgan Stanley
New York
|
-$713K |
| 4 |
BlackRock
New York
|
-$711K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$504K |
UBX Hedge Fund Activity: Q4 2021 in Review
71 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q4 2021, worth a combined $21.3M — down 49% from $42M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of UBX and 17 opened new positions — a net loss of 12 holders — while 12 trimmed existing stakes and 21 added.
The largest buyer was Marshall Wace, adding an estimated $1.68M. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $1.63M sold.
- 71 institutional investors held Unity Biotechnology (UBX) as of Q4 2021, down from 84 in Q3 2021.
- Funds reported $21.3M of Unity Biotechnology stock for Q4 2021, down 49% quarter-over-quarter.
- 17 funds opened new Unity Biotechnology positions in Q4 2021 and 29 closed out, a net change of -12 holders.
- The largest Unity Biotechnology buyer in Q4 2021 was Marshall Wace, an estimated $1.68M added.
- The largest Unity Biotechnology seller in Q4 2021 was Jacobs Levy Equity Management, an estimated $1.63M sold.
Based on aggregated 13F filings for Q4 2021.